Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 11

Imetelstat and IMerge Trial Review

,

Panelists discuss how imetelstat, a telomerase inhibitor recently approved by the FDA on June 6, 2024, works and its efficacy as demonstrated in the IMerge trial, while highlighting key adverse events that community oncologists should be vigilant about when considering this treatment for patients with lower-risk MDS.

Video content above is prompted by the following:

  • Please review imetelstat, including mechanism of action and FDA approval (imetelstat, June 6, 2024).
  • IMerge trial (Platzbecker U, et al. Lancet. 2024;403(10423):249-260.)
  • What are some key adverse events community oncologists should be aware of with imetelstat?